[go: up one dir, main page]

MX2012012115A - Formulacion estable de mia/cd-rap. - Google Patents

Formulacion estable de mia/cd-rap.

Info

Publication number
MX2012012115A
MX2012012115A MX2012012115A MX2012012115A MX2012012115A MX 2012012115 A MX2012012115 A MX 2012012115A MX 2012012115 A MX2012012115 A MX 2012012115A MX 2012012115 A MX2012012115 A MX 2012012115A MX 2012012115 A MX2012012115 A MX 2012012115A
Authority
MX
Mexico
Prior art keywords
rap
stable aqueous
formulations
formulation
mia
Prior art date
Application number
MX2012012115A
Other languages
English (en)
Other versions
MX344732B (es
Inventor
Klaus Hellerbrand
Rainer Sigl
Original Assignee
Scil Technology Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scil Technology Gmbh filed Critical Scil Technology Gmbh
Publication of MX2012012115A publication Critical patent/MX2012012115A/es
Publication of MX344732B publication Critical patent/MX344732B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se relaciona con formulaciones acuosas estables que comprenden al menos 5mg/mL de CD-RAP y un aminoácido cargado, el aminoácido tiene preferentemente una carga neta a un pH entre aproximadamente 6 y 8. Los ingredientes de la formulación preferentemente proporcionan estabilidad sobre ciclos repetidos de congelamiento-deshielo. En un aspecto preferido, la formulación es para usarse en terapia, preferentemente para usarse en el tratamiento contra trastornos inflamatorios, preferentemente osteoartritis. Más aún, se proporciona un kit que comprende la formulación de la invención.
MX2012012115A 2010-04-27 2011-04-27 Formulacion estable de mia/cd-rap. MX344732B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10161160 2010-04-27
PCT/EP2011/056622 WO2011134979A2 (en) 2010-04-27 2011-04-27 Stable mia/cd-rap formulation

Publications (2)

Publication Number Publication Date
MX2012012115A true MX2012012115A (es) 2013-01-29
MX344732B MX344732B (es) 2017-01-04

Family

ID=43806879

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012012115A MX344732B (es) 2010-04-27 2011-04-27 Formulacion estable de mia/cd-rap.

Country Status (20)

Country Link
US (2) US9511116B2 (es)
EP (1) EP2563809B1 (es)
JP (2) JP2013525406A (es)
KR (1) KR101880905B1 (es)
CN (1) CN102869679B (es)
AU (1) AU2011247659B2 (es)
BR (1) BR112012027361A2 (es)
CA (1) CA2792965A1 (es)
CL (1) CL2012002948A1 (es)
CO (1) CO6592098A2 (es)
IL (1) IL222712B (es)
MA (1) MA34225B1 (es)
MX (1) MX344732B (es)
MY (1) MY160916A (es)
NZ (1) NZ601927A (es)
PH (1) PH12012502140A1 (es)
RU (2) RU2588658C2 (es)
SG (3) SG10201908916UA (es)
WO (1) WO2011134979A2 (es)
ZA (1) ZA201206235B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012027361A2 (pt) * 2010-04-27 2021-04-27 Scil Technology Gmbh formulação mia/cd-rap estável.
JPWO2014098232A1 (ja) * 2012-12-21 2017-01-12 学校法人東京理科大学 Ｐｉ３キナーゼ阻害剤を含む医薬組成物、ビタミンｄ受容体に作用する化合物を含む医薬組成物、凍結乾燥組成物、凍結乾燥組成物の製造方法、及び経肺投与用医薬組成物
EP3148568A4 (en) * 2014-05-28 2018-01-17 Nono Inc. Lyophilized formulation of tat-nr2b9c with acetylation scavenger
WO2017046314A2 (en) * 2015-09-18 2017-03-23 Sanofi Improvement of expression and folding in the manufacturing process of cd-rap by using a cd-rap precursor protein
KR20190027878A (ko) * 2016-07-13 2019-03-15 리폼 바이오로직스, 엘엘씨 치료 단백질 제제용 안정화 부형제
EP3549946A4 (en) * 2016-11-29 2020-10-21 Spiber Inc. COMPOSITION OF PROTEIN, ITS PRODUCTION PROCESS AND PROCESS FOR IMPROVING THERMAL STABILITY
KR102692727B1 (ko) * 2017-03-31 2024-08-08 메이지 세이카 파루마 가부시키가이샤 수성 제제 및 주사기 내 수성 제제, 및 항체 단백질 탈응집제 및 항체 단백질 탈응집 방법
KR20190066941A (ko) 2017-12-06 2019-06-14 주식회사 에코에너젠 반도체 제조 공정의 복합오염물질 저감 장치
BR112021026009A2 (pt) * 2019-06-24 2022-02-08 Hangzhou Dac Biotech Co Ltd Composições líquida e farmacêutica, conjugados dos análogos de tubulisina, análogo de tubulisina, agentes de ligação celular e sinérgico, e, célula tumoral
CN112386575B (zh) * 2019-08-19 2023-03-21 鲁南制药集团股份有限公司 一种代谢调节融合蛋白的冻干制剂
KR102427935B1 (ko) 2022-05-23 2022-08-03 주식회사 동우이엔티 습식 스크러버를 포함한 입자상 및 가스상 오염물질이 혼합된 복합가스의 동시 처리가 가능한 습식 전기집진시스템

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54147916A (en) * 1978-05-12 1979-11-19 Sumitomo Chem Co Ltd Preparation of urokinase injection
DE2916711A1 (de) 1979-04-25 1980-11-06 Behringwerke Ag Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
US4783441A (en) 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
US4374763A (en) * 1979-09-17 1983-02-22 Morishita Pharmaceutical Co., Ltd. Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof
EP0158487B1 (en) 1984-04-09 1991-08-28 Takeda Chemical Industries, Ltd. Stable composition of interleukin-2
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
GB8903593D0 (en) 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
FR2684878B1 (fr) * 1991-12-12 1994-02-11 Roussel Uclaf Composition pharmaceutique stabilisee d'il2 humaine recombinante non glycosylee sous forme reduite et son procede de preparation.
DE4242863A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
ZA945278B (en) 1993-07-20 1996-01-19 Boehringer Mannheim Gmbh Melanoma-inhibiting protein
US5580856A (en) * 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
RU2497500C2 (ru) * 1995-07-27 2013-11-10 Джинентех, Инк Стабильная изотоническая лиофилизированная протеиновая композиция
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
AU5702099A (en) 1998-09-01 2000-03-21 Millennium Pharmaceuticals, Inc. A novel protein related to melanoma-inhibiting protein and uses thereof
US20020103360A1 (en) * 1998-09-01 2002-08-01 Yang Pan Novel protein related to melanoma-inhibiting protein and uses thereof
EP1025871A1 (en) 1999-01-28 2000-08-09 F. Hoffmann-La Roche Ag Use of a melanoma inhibiting activity factor (MIA) for cartilage and bone repair
CZ299516B6 (cs) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
RU2197238C2 (ru) * 1999-11-22 2003-01-27 Российский научный центр "Восстановительная травматология и ортопедия" им. академика Г.А. Илизарова Способ профилактики и лечения остеоартроза, средство для его осуществления и способ получения средства для лечения остеоартроза
US6743446B2 (en) * 1999-12-15 2004-06-01 The Ohio State University Research Foundation Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers
AU2001232967A1 (en) 2000-01-25 2001-08-07 Hyseq, Inc. Methods and materials relating to novel growth regulatory-like polypeptides and polynucleotides
JP2003527435A (ja) * 2000-03-23 2003-09-16 アクゾ・ノベル・エヌ・ベー 免疫療法におけるｍｉａの使用
JP2005521640A (ja) * 2001-11-13 2005-07-21 ジェネンテック・インコーポレーテッド Ａｐｏ−２リガンド／ＴＲＡＩＬ製剤
DK1478394T3 (da) * 2002-02-27 2008-10-13 Immunex Corp Stabiliseret TNFR-Fc formulation med arginin
AU2003259696A1 (en) * 2002-08-08 2004-02-25 Nuvelo, Inc. Methods and materials relating to novel growth regulatory-like polypeptides and polynucleotides
DE10360483B4 (de) 2003-12-22 2007-11-15 Scil Proteins Gmbh Expressionsvektor und dessen Verwendung
TW200806317A (en) * 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
SI2081551T1 (sl) * 2006-10-06 2013-05-31 Scil Technology Gmbh Tvorba posušenega rekonstituiranega vezikla za farmacevtsko uporabo
US20090060906A1 (en) * 2007-01-09 2009-03-05 Wyeth Anti-IL-13 antibody formulations and uses thereof
BR112012027361A2 (pt) * 2010-04-27 2021-04-27 Scil Technology Gmbh formulação mia/cd-rap estável.

Also Published As

Publication number Publication date
RU2012144771A (ru) 2014-06-10
CA2792965A1 (en) 2011-11-03
US20170042971A1 (en) 2017-02-16
JP6078129B2 (ja) 2017-02-08
SG10201502398RA (en) 2015-05-28
SG183561A1 (en) 2012-09-27
ZA201206235B (en) 2021-04-28
JP2013525406A (ja) 2013-06-20
RU2739078C2 (ru) 2020-12-21
PH12012502140A1 (en) 2013-02-04
US20130137639A1 (en) 2013-05-30
IL222712B (en) 2018-02-28
KR101880905B1 (ko) 2018-07-23
RU2016118646A3 (es) 2019-06-20
RU2588658C2 (ru) 2016-07-10
MY160916A (en) 2017-03-31
US9907829B2 (en) 2018-03-06
CN102869679B (zh) 2015-11-25
CO6592098A2 (es) 2013-01-02
RU2016118646A (ru) 2018-11-02
WO2011134979A2 (en) 2011-11-03
EP2563809A2 (en) 2013-03-06
US9511116B2 (en) 2016-12-06
AU2011247659A1 (en) 2012-09-06
CN102869679A (zh) 2013-01-09
IL222712A0 (en) 2012-12-31
WO2011134979A3 (en) 2012-06-14
BR112012027361A2 (pt) 2021-04-27
MA34225B1 (fr) 2013-05-02
JP2016034958A (ja) 2016-03-17
KR20130086531A (ko) 2013-08-02
HK1179273A1 (zh) 2013-09-27
EP2563809B1 (en) 2020-04-01
SG10201908916UA (en) 2019-11-28
NZ601927A (en) 2013-07-26
AU2011247659B2 (en) 2014-07-24
MX344732B (es) 2017-01-04
CL2012002948A1 (es) 2013-02-15
WO2011134979A9 (en) 2012-08-16

Similar Documents

Publication Publication Date Title
MY160916A (en) Stable mia/cd-rap formulation
MX2012010161A (es) Metodo para tratar el mal de parkinson.
EA201101243A1 (ru) 3h-имидазо[4,5-c]пиридин-6-карбоксамиды в качестве противовоспалительных средств
EA202091303A3 (ru) Композиция ингибитора jak для местного применения
JP2016516023A5 (es)
NZ591810A (en) Pharmaceutical compositions and related methods of delivery the composition comprises a medium chain fatty acid
MX2010004647A (es) Producto para cuidado oral y metodos de uso del mismo.
NZ610911A (en) Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same
PH12013500938A1 (en) Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
TW200727903A (en) Stable pharmaceutical compositions of 5, 10 methylenetetrahydrofolate
WO2009127669A3 (en) Ido inhibitors and therapeutic uses thereof
PH12015500864A1 (en) Liquid formulation comprising gm-csf neutralizing compound
ZA201607097B (en) Liquid formulation comprising gm-csf neutralizing compound
PT2459153E (pt) Composição farmacêutica ou cosmética ou dietética tendo o efeito de favorecer a pigmentação capilar
GB2523707A (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
EA200400888A1 (ru) Фармацевтически приемлемые тельца, несущие фосфат глицерина
WO2011139256A3 (en) Stable rosuvastatin formulations
PT1638582E (pt) Uso de ácido hialurónico para a preparação de composições para o tratamento de aftas recorrentes da cavidade bucal
TR200806300A2 (tr) Çözünürlük artırıcı farmasötlk formulasyon
NZ719321A (en) Storage stable lyophilized tripeptide formulations
BRPI0412453A (pt) uso do ácido ascórbico ou um sal fisiologicamente aceitável do mesmo
HK1209027A1 (en) Vesicular formulations, uses and methods
EA200500687A1 (ru) Применение дистронциевой соли 2-[n,n-ди(карбоксиметил)амино]-3-циано-4-карбоксиметилтиофен-5-карбоновой кислоты при получении лекарственных средств, предназначенных для лечения гастродуоденальной боли
IT1394921B1 (it) Uso di composti come principi attivi per migliorare l'azione di riparazione cellulare dell'epidermide umana, e composizioni farmaceutiche e cosmetiche che li contengono
UA53379U (ru) Суспензионный крем для лечения воспалительных стоматологических заболеваний

Legal Events

Date Code Title Description
FG Grant or registration